Sanjeev Kotwal MD FRCS(Urol) FEBU

@GuysUrology @prokarurol Congratulations chief @prokarurol Wish you a retirement as exciting as your career.

What an emotional day. Last prostate clinic and one stop for @prokarurol before his retirement. Friend, mentor, colleague. 28 yrs service. Innovator, technology enthusiast and true legend of urology. We will all miss him.

@olly_leeds @LeedsHospitals @FocalOneHIFU @joshuarobotics @veerukasi @ConorDevlin20 @LabBryant Thank you for your support @olly_leeds. You were missed today 🙏🏼.

@UroDocKotwal @LeedsHospitals @FocalOneHIFU @joshuarobotics @veerukasi @ConorDevlin20 @LabBryant Fantastic work all 👏

Application for RCSEng approved #Robotic Pelvic Oncology Fellowship at @LTHT in Leeds is open. Please apply on @nhsjobs. Our fellowship offers training in #RARP #iRARC #roboticreconstruction with one of the busiest Uro-oncology team in the @UK . Closing date 20.01.2026.

New in European Urology By @OncoBellmunt Final subgroup analysis from the JAVELIN Bladder 100 trial confirms the long-term survival benefit of avelumab first-line maintenance in patients with nonvisceral or lymph node–only metastatic urothelial carcinoma (mUC). 🔹 OS: 31.4 vs 17.1 months (HR 0.60) in nonvisceral disease 🔹 OS: 31.9 vs 22.7 months (HR 0.86) in LN-only disease 🔹 Safety consistent with overall population These results reinforce avelumab maintenance as the standard post-chemotherapy approach for patients with advanced urothelial carcinoma. 📖 European Urology 2025; 88:331–338 🔗 buff.ly/XOq92OW #EuropeanUrology #BladderCancer #UrothelialCarcinoma #Avelumab #Immunotherapy #Oncology #ClinicalTrials

💡 CheckMate 901 – Lymph Node–Only Metastatic Urothelial Carcinoma Exploratory post hoc analysis shows that nivolumab + gemcitabine–cisplatin improves survival and deepens responses in patients with LN-only metastatic UC. 🔹 Median OS: 46.3 vs 24.9 months 🔹 Median PFS: 30.5 vs 8.8 months 🔹 41% of complete responders remained treatment-free 📖 European Urology 2025 👉 buff.ly/ZLwhB29

Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With #BladderCancer jamanetwork.com/journals/jama/… In this randomized clinical trial of 338 patients with nonmetastatic bladder cancer across nine UK🇬🇧 centers, robot-assisted radical cystectomy with intracorporeal reconstruction was compared to open radical cystectomy to assess recovery and morbidity. The robotic approach resulted in a modest but statistically significant increase in days alive and out of the hospital within 90 days (median 82 vs 80 days), and was associated with fewer thromboembolic and wound complications, as well as better short-term quality of life and less disability at 5 and 12 weeks. However, there were no differences in cancer recurrence or overall survival at a median follow-up of 18.4 months, and the clinical significance of the improved recovery metrics remains uncertain. James  Catto @p_khetrapal @federicc @UroRobot @ProfShamimKhan1 @AndyFeber @acesridhar @pjscharlesworth @Blick_CG @marcuskwesi @ProfSyedHussain @UroDocKotwal @AKoupparis @nikhilvasdevuro @vishhanchanale @OncoAlert 🚨

@MarioNawfal Hi! @MarioNawfal @elonmusk. We have been using Da Vinci surgical robot for Prostate , Bladder and Kidney cancer surgeries for over 2 decades. surgical robot - tens of thousand such urological surgeries already undertaken with much better results than recent Hugo robotic system.

🚨 ROBOTS CAN NOW HELP WITH SURGERY — AND THEY’RE ACTUALLY GOOD AT IT Medtronic tested its Hugo robot in 137 real surgeries — fixing prostates, kidneys, and bladders — and the results were better than doctors expected. Complication rates were super low: just 3.7% for prostate surgeries, 1.9% for kidney surgeries, and 17.9% for bladder surgeries, all beating safety goals from years of research. The robot got a 98.5% success rate, way above the 85% goal — meaning it didn’t just pass the test, it basically set the curve. Out of 137 surgeries, only 2 needed to switch back to regular surgery — 1 because of a robot glitch, and 1 because of a tricky patient case. This doesn’t mean robots are replacing surgeons tomorrow, but it does mean your next doctor might have a very expensive metal sidekick. Source: RTTNews

Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial ascopubs.org/doi/10.1200/JC… This prospective, randomized study evaluated whether using flexible cystoscopic biopsy combined with multiparametric MRI (mpMRI) could expedite treatment for patients with suspected muscle-invasive #BladderCancer (MIBC) compared to the traditional approach of staging with transurethral resection of bladder tumor (TURBT). Conducted across 17 UK🇬🇧 hospitals, the study found that initial staging with mpMRI was feasible and significantly reduced the median time to correct treatment (TTCT) for MIBC by 45 days compared to TURBT, without negatively impacting patients with non–muscle-invasive disease. These findings support incorporating mpMRI early in the diagnostic pathway to accelerate definitive treatment for patients with suspected MIBC. @DrRashidAmir @HattieMintz @DaUroKing @lgommersall @PaulHunterCamp1 @drgvkswamy @UroDocKotwal @davidkmak @MoheeAmar @docpp1 @Prof_Nick_James @Shaista_Hafeez

@UroDocAsh @VivekGRamaswamy @AshTewariMD @narendramodi That’s great news @nycrobotics. Congratulations Ash

Explains why Ash Tewari skipped #GU25 this year!

@DrSJaishankar @POTUS @VP @washingtonpost conveniently forgot to mention Indian FM @DrSJaishankar name among the list of foreign dignitaries attending President Trump’s inauguration ceremony. He was sitting right in front of the @POTUS in the front row 🤔

A great honour to represent India at the inauguration ceremony of @POTUS President Donald J Trump and @VP Vice President JD Vance in Washington DC today. 🇮🇳 🇺🇸

@washingtonpost failed to mention @DrSJaishankar name among the foreign leaders who attended Trump’s inauguration ceremony, despite him sitting right in front of the @POTUS in the front row. Surely, a bit odd 🤔!!

Original Reports | Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial ⁦@BAUSurology⁩ ⁦@UniversityLeeds⁩ ⁦@LTHTResearch⁩ linkedin.com/posts/oncoaler…

@VickersBiostats @TouijerKarim Great stats work.However, primary lymphatic drainage area for prostate is internal iliac/obturator nodes. This is where we find micro mets and as that area was excluded in limited PLND arm, this trial has only measured protective effect of (real-world) limited PLND on metastasis.

First single center RCT in the modern era to show a treatment effect on metastasis. Extended LND during radical prostatectomy superior to limited LND europeanurology.com/article/S0302-… @TouijerKarim

@Issarami It used to be around 25% for ORC in Leeds. It dropped to <5% once we switched to iRARC from 2016 onwards.

37% transfusion rate🤯

Long-Term Second Malignancies in Prostate Cancer Patients Treated With Low-Dose-Rate Brachytherapy and Radical Prostatectomy | Journal of Urology auajournals.org/doi/10.1097/JU…

Offer patients with cN1 disease a local treatment (either radical prostatectomy or IMRT/VMAT plus IGRT) plus long-term androgen-deprivation therapy. #ProstateCancer #EAUguidelines uroweb.org/guidelines/pro…

3rd Basic Urology Skills Course well under way @LeedsHospitals. Full hands simulation on TURP, scrotal exploration, cystoscopy, URS, stent, circumcision, troubleshooting with catheters. @MedEdLeeds @BAUSurology @BSoT_UK @RCSnews @RCSEd @shekharbiyani @LukeHChan

Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC… 9% survival advantage: 5-year OS was 66% versus 57%